Palatin Technologies, Inc.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Palatin Technologies (NYSEAMERICAN:PTN) said it is prioritizing development of next-generation melanocortin-4 receptor, or MC4R, agonists for rare and syndromic obesity disorders, while also seeking additional financing to support its programs and address a going-concern uncertainty disclosed alongside fiscal 2026 results. President and Chief Executive Officer Carl Spana said the company is initially targeting hypothalamic obesity,

Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript

Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePRINCETON, N.J., Sept. 28, 2026Programs are focused on rare obesity di

Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in the first half of calendar 2027, with initial data targeted in the second half of 2027 Oral MC4R selective agonist Phase 1 SAD/MAD study targeted to initiate in the second half of calendar 2027, with initial data …